Cardio Diagnostics Holdings (NASDAQ: CDIO) has scheduled an investor conference call for Dec. 10, 2026, at 11 a.m. CT to update shareholders on its precision cardiovascular disease detection and prevention technologies, including its commercially available Epi+Gen CHD(TM) and PrecisionCHD(TM) tests. The call will cover ongoing and planned studies, reimbursement progress, and strategic growth initiatives, with a particular focus on non-obstructive coronary artery disease (NOCAD), a condition that can be missed by conventional diagnostic methods.
Management plans to present data supporting its blood-based technology for detecting NOCAD and to discuss its anticipated request for U.S. Food and Drug Administration (FDA) Breakthrough Device designation. The call will also address the commencement of testing in India, Cardio Diagnostics' first international market, through partnerships with Dr. Lal PathLabs and Aimil. The company said its approach combines epigenetics, genetics, and artificial intelligence to provide scalable cardiovascular risk assessment and early disease detection through standard blood samples.
The announcement matters because NOCAD often goes undetected in standard cardiac evaluations, leaving patients at risk of adverse events despite normal-looking arteries. A blood-based test that flags NOCAD could help clinicians identify high-risk individuals earlier, potentially reducing costly emergency interventions and improving outcomes. If the company secures FDA Breakthrough Device designation, it could benefit from prioritized regulatory review, accelerating U.S. market access and strengthening reimbursement conversations with payers. For investors, the Dec. 10 call is a key checkpoint on study data, reimbursement progress, and international expansion, all of which will shape the commercial trajectory of the company's tests.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. Its proprietary AI-driven Integrated Genetic-Epigenetic Engine, or Core Technology, is designed to support scalable risk assessment and early disease detection. The latest news and updates relating to CDIO are available in the company's newsroom at https://ibn.fm/CDIO. To view the full press release, visit https://ibn.fm/tEHRV.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, including editorial syndication to 5,000+ outlets and corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by BioMedWire, see https://www.BioMedWire.com/Disclaimer.


